AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019: Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

April 16, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Apr 16, 2019--The “Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 4, 19, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

Reasons to Buy

Key Topics Covered

1. Introduction

2. Post-Traumatic Stress Disorder (PTSD) - Overview

3. Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development

4. Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

5. Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development

6. Post-Traumatic Stress Disorder (PTSD) - Drug Profiles

7. Post-Traumatic Stress Disorder (PTSD) - Dormant Projects

8. Post-Traumatic Stress Disorder (PTSD) - Discontinued Products

9. Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones

10. Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xezxrm

View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005514/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/16/2019 07:27 AM/DISC: 04/16/2019 07:26 AM

http://www.businesswire.com/news/home/20190416005514/en